Detalhe da pesquisa
1.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 403(10434): 1341-1350, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38521086
2.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med
; 385(20): 1856-1867, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534429
3.
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
JAMA Oncol
; 10(2): 185-192, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095881